Polpharma Biologics

News

Sandoz launches first biosimilar Tysabri in US

Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.

News

Polpharma Bio gets first EU okay for Tysabri biosimilar

Polpharma Biologics has said it is the first company to get approval in the EU for a biosimilar version of Biogen’s blockbuster multiple sclerosis therapy Tysabri.

News

TransThera's resistant biliary cancer drug cleared in China

TransThera's Yochanra has been cleared in China as the world's first drug that can overcome resistance to FGFR inhibitors in cholangiocarcinoma.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks